Federal Circuit Upholds Revival of Amarin’s Vascepa Patent Dispute Against Hikma

The Federal Circuit has decided not to have the full appellate court reconsider a panel’s decision that revived Amarin Pharma Inc.’s “skinny label” patent dispute against the British pharmaceutical company, Hikma. This development revolves around Amarin’s product, Vascepa, and the ongoing legal conflict concerning the “skinny label” approach used by generic manufacturers to sidestep patents related to specific uses of a drug. The legal intricacies of this case underscore the challenges faced by pharmaceutical companies in defending their patent rights against generic competitors. Further details of the judgment can be found in the full article on Law360, as reported by Adam Lidgett.